Creative Medical Technology Holdings, Inc. (CELZ)
| Previous Close | 4.3500 |
| Open | 4.5400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.3937 - 4.3937 |
| 52 Week Range | 3.9300 - 10.2812 |
| Volume | |
| Avg. Volume | 218,145 |
| Market Cap | 5.961M |
| Beta (5Y Monthly) | 5.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Creative Medical Technology Holdings Provides Corporate Update
PHOENIX, March 27, 2024--Creative Medical Technology Holdings, Inc., ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.
- Business Wire
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
PHOENIX, March 07, 2024--Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals.
- Business Wire
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
PHOENIX, March 06, 2024--Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CELZ-101, ImmCelzTM. This cutting-edge therapy is aimed at preventing allograft rejection in patients undergoing pancreatic islet
